bioRxivNeurosciencePreprint
Contrasting effects of chronic lithium, haloperidol and olanzapine exposure on synaptic clusters in the rat prefrontal cortex
Els F. HalffiD, Marie-Caroline CôteliD, Sridhar NatesaniD, Richard McQuadeiD, Chris J. OttleyiD, Deepak P. Srivastiva, Oliver David HowesiD, Anthony Christopher VernoniD
Abstract
The pathophysiology of the majority of neuropsychiatric disorders, including schizophrenia and mood disorders, involves synaptic dysfunction and/or loss, manifesting as lower levels of several presynaptic and postsynaptic marker proteins. Whether chronic exposure to antipsychotic drugs may contribute to this pattern of synaptic loss remains controversial. In contrast, the mood stabiliser lithium has shown to exhibit neurotrophic actions and is thought to enhance synapse formation. Whilst these data are not unequivocal, they suggest that antipsychotic drugs and lithium have contrasting effects on synapse density. We therefore investigated the effect of chronic exposure to lithium and to two different antipsychotics, haloperidol and olanzapine, on presynaptic Synaptic Vesicle glycoprotein 2A (SV2A) and postsynaptic Neuroligin (NLGN) clusters in the rat frontal cortex. Chronic exposure (28 days) to haloperidol (0.5 mg/kg/d) or olanzapine (7.5 mg/kg/d) had no effect on either SV2A or NLGN clusters and no overall effect on synaptic clusters. In contrast, chronic lithium exposure (2 mmol/L eq./d) significantly increased NLGN cluster density as compared to vehicle, but did not affect either SV2A or total synaptic clusters. These data are consistent with and extend our prior work, confirming no effect of either antipsychotics or lithium on SV2A clustering, but suggest contrasting effects of these drugs on the post-synapse. Although caution needs to be exerted when extrapolating results from animals to patients, these data provide clarity with regard to the effect of antipsychotics and lithium on synaptic markers, thus facilitating discrimination of drug from illness effects in human studies of synaptic pathology in psychiatric disorders.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Phencyclidine-induced psychosis causes hypersynchronization and disruption of connectivity within prefrontal-hippocampal circuits that is rescued by antipsychotic drugs
Cristina Delgado-Sallent, Pau Nebot, … Maria Victoria Puig·bioRxiv·Feb 3, 2021
- Effects of Antipsychotic Drugs and Potassium Channel Modulators on Cognition-related Local Field Potential Spectral Properties in Mouse Hippocampus and Frontal Cortex
Dechuan Sun, Mojtaba Kermani, … Chris R. French·NeuropharmacologyPeer-reviewed·Apr 23, 2021
- The mood stabilizer lithium slows down synaptic vesicle cycling at glutamatergic synapses
Willcyn Tang, Bradley Cory, … Marc L. Fivaz·NeuroMolecular MedicinePeer-reviewed·Nov 27, 2022
- Activation of prefrontal parvalbumin interneurons ameliorates treatment-resistant working memory deficit even under continuous antipsychotic treatment in a mouse model of schizophrenia
Yosefu Arime, Yoshito Saitoh, … Noriaki Ohkawa·bioRxiv·Feb 27, 2023
- Modulating D1 rather than D2 receptor-expressing spiny-projection neurons corresponds to optimal antipsychotic effect
Seongsik Yun, Ben Yang, … Jones G. Parker·Nature NeurosciencePeer-reviewed·Jul 13, 2023
- Matching drug transcriptional signatures to rare losses disrupting synaptic gene networks identifies known and novel candidate drugs for schizophrenia
Daniele Merico, Xiao Wang, … Anne S. Bassett·bioRxiv·Feb 19, 2018